Related Experiment Videos
Biochemical abnormalities in patients with multiple chemical sensitivities
Summary
Patients with Multiple Chemical Sensitivities (MCS) exhibit biochemical abnormalities, particularly low antioxidant levels. Supplementation with antioxidants improved symptoms in a significant portion of patients, suggesting a role in managing MCS illness.
Area of Science:
- Biochemistry
- Environmental Medicine
- Clinical Nutrition
Background:
- Multiple Chemical Sensitivities (MCS) patients present with numerous physiological and biochemical abnormalities compared to allergic controls.
- Associated conditions include mitral valve prolapse, hypothyroidism, and metabolic disturbances in amino and essential fatty acids.
- Deficiencies in magnesium and Vitamin B6 are equally prevalent in MCS patients and controls.
Purpose of the Study:
- To investigate the physiological and biochemical abnormalities in patients with Multiple Chemical Sensitivities (MCS).
- To explore the potential role of impaired antioxidant levels in MCS and its contribution to hypersensitivity.
- To evaluate the efficacy of antioxidant supplementation in improving clinical outcomes for MCS patients.
Main Methods:
- Assessment of erythrocyte superoxide dismutase (ESOD) and glutathione peroxidase (EGPx) activity.
- Analysis of amino acid excretion and leucocyte vitamin C levels.
- Clinical evaluation of patients before and after antioxidant treatment.
Main Results:
- Significantly impaired erythrocyte ESOD activity (89%) and EGPx activity (48%) were observed in MCS patients.
- 41% of MCS patients showed impaired essential amino acid excretion, and low vitamin C levels were noted in some.
- Antioxidant supplementation led to major clinical improvement in 25% and limited relief in 18% of MCS patients.
Conclusions:
- Impaired antioxidant levels are frequent in MCS patients and may contribute to hypersensitivity.
- Antioxidant deficiencies could play a role in the general ill health experienced by MCS patients.
- Supplementation with antioxidants shows promise for improving clinical symptoms in a subset of MCS patients.